Heparin rebound: a comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery.

[1]  J. Branch,et al.  HEPARIN SENSITIVITY COMPARISON OF THE ACT, SCT, AND APTT , 1989 .

[2]  S. Gundry,et al.  Postoperative bleeding in cardiovascular surgery. Does heparin rebound really exist? , 1989, The American surgeon.

[3]  R. Skidgel,et al.  Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins. , 1989, Anesthesiology.

[4]  T. Hooper,et al.  The use of the Hemochron in assessment of heparin reversal after cardiopulmonary bypass , 1988 .

[5]  G. Gravlee,et al.  Variability of the activated coagulation time. , 1988, Anesthesia and analgesia.

[6]  L. van Neste,et al.  Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. , 1987, American journal of clinical pathology.

[7]  F. Laduca,et al.  Neutralization of Heparin Using a Protamine Titration Assay and the Activated Clotting Time Test , 1987, The Journal of ExtraCorporeal Technology.

[8]  G. Savidge,et al.  Protamine sulphate and heparin rebound following open-heart surgery. , 1986, The Journal of cardiovascular surgery.

[9]  B. Baudet,et al.  Determination of "in vitro" degradation of protamine in plasma by three different methods. , 1986, Thrombosis research.

[10]  S. Gundry,et al.  Failure of automated protamine titration to determine the protamine reversal dose of systemic heparin: comparison with other methods. , 1986, Current surgery.

[11]  J. Walenga,et al.  Biochemical and Pharmacologic Studies on the Protamine Interactions with Heparin, Its Fractions and Fragments , 1985, Seminars in thrombosis and hemostasis.

[12]  P. Diemunsch,et al.  Heparin monitoring during cardiopulmonary bypass. , 1984, Annals of clinical and laboratory science.

[13]  H. Stormorken,et al.  The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. , 1984, Scandinavian journal of thoracic and cardiovascular surgery.

[14]  G. Gauvin,et al.  Anticoagulant Monitoring and Neutralization during Open Heart Surgery—A Rapid Method for Measuring Heparin and Calculating Safe Reduced Protamine Doses , 1983, Anesthesia and analgesia.

[15]  D. Benayahu,et al.  Comparative study of protamine chloride and sulphate in relation to the heparin rebound phenomenon. , 1983, Thrombosis research.

[16]  J. Ankeney,et al.  Activated Coagulation and Activated Partial Thromboplastin Times in Assessment and Reversal of Heparin‐Induced Anticoagulation for Cardiopulmonary Bypass , 1983, Anesthesia and analgesia.

[17]  K. Taylor,et al.  Protamine titration after cardiopulmonary bypass , 1983, Anaesthesia.

[18]  S. Thomas,et al.  The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[19]  A. Montoya,et al.  Management of postoperative heparin rebound following cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[20]  A. Schwartz,et al.  Monitoring heparin anticoagulation and its neutralization. , 1981, The Annals of thoracic surgery.

[21]  I. Fabian,et al.  Mechanism of heparin rebound: in vitro study. , 1980, Thrombosis research.

[22]  T. Kaul,et al.  Heparin administration during extracorporeal circulation: heparin rebound and postoperative bleeding. , 1979, The Journal of thoracic and cardiovascular surgery.

[23]  M. Lie,et al.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. , 1977, Thrombosis research.

[24]  R. Ponlot,et al.  Hæmostasis Disorders in Open Heart Surgery with Extracorporeal Circulation: Importance of the Platelet Function and the Heparin Neutralization , 1977, Vox sanguinis.

[25]  R. Ponlot,et al.  Haemostasis Disorders in Open Heart Surgery with Extracorporeal Circulation , 1977 .

[26]  L. Jaques,et al.  The observation of heparin on endothelium after injection. , 1976, Thrombosis research.

[27]  J. W. Bland,et al.  Successful Use of a Reduced Dose of Protamine After Cardiopulmonary Bypass , 1976, Anesthesia and analgesia.

[28]  F. Bachmann,et al.  The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. , 1975, The Journal of thoracic and cardiovascular surgery.

[29]  K. Mattox,et al.  Use of the activated coagulation time in intraoperative heparin reversal for cardiopulmonary operations. , 1975, The Annals of thoracic surgery.

[30]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[31]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[32]  N. Ellison,et al.  Heparin rebound. Studies in patients and volunteers. , 1974, The Journal of thoracic and cardiovascular surgery.

[33]  S. Gollub.  Heparin rebound in open heart surgery. , 1967, Surgery, gynecology & obstetrics.

[34]  P. Frick,et al.  The mechansim of heparin rebound after extracorporeal circulation for open cardiac surgery. , 1966, Surgery.

[35]  M. Andersen,et al.  Experimental studies of heparin-protamine activity with special reference to protamine inhibition of clotting. , 1959, Surgery.

[36]  J. Nyboer,et al.  The use of the heart-lung apparatus in human cardiac surgery. , 1957, The Journal of thoracic surgery.

[37]  M. Peng,et al.  Prediction of blood volume and adiposity in man from body weight and cube of height. , 1956, Metabolism: clinical and experimental.